<DOC>
	<DOCNO>NCT02741245</DOCNO>
	<brief_summary>This study evaluate efficacy safety tolerability 2 dose level MK-0653H Japanese participant . The primary hypothesis administration MK-0653H safe tolerable MK-0653H superior single entity Ezetimibe Rosuvastatin percent reduction baseline low-density lipoprotein-cholesterol ( LDL-C ) 12 week treatment .</brief_summary>
	<brief_title>A Study Efficacy Safety MK-0653H Japanese Participants With Hypercholesterolemia ( MK-0653H-832 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Japanese Outpatient hypercholesterolemia Female participant reproductive potential agree remain abstinent use ( partner use ) two acceptable method birth control date sign informed consent 14 day last dose study drug Will maintain stable diet consistent Japan Atherosclerosis Society Guideline 2012 ( JAS 2012 ) prevention atherosclerotic cardiovascular disease duration study Uncontrolled hypertension ( treat untreated ) Uncontrolled type 1 type 2 diabetes mellitus History coronary artery disease ( CAD ) , CADequivalent disease Familial hypercholesterolemia undergone LDL apheresis Uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins Has gastrointestinal tract bypass , significant intestinal malabsorption History cancer within past 5 year ( except successfully treat dermatological basal cell squamous cell carcinoma situ cervical cancer ) Human Immunodeficiency Virus ( HIV ) positive History drug/ alcohol abuse within past 5 year psychiatric illness adequately control stable pharmacotherapy Consumes 25 g alcohol per day Currently follow excessive weight reduction diet Currently engage vigorous exercise regimen ( e.g . ; marathon training , body build train etc . ) intend start training study Hypersensitivity intolerance Ezetimibe Rosuvastatin Myopathy rhabdomyolysis Ezetimibe statin Pregnant lactating Taking investigational drug and/or take investigational drug within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>